Arcadia Biosciences Inc
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief,… Read more
Arcadia Biosciences Inc (RKDA) - Total Liabilities
Latest total liabilities as of September 2025: $3.14 Million USD
Based on the latest financial reports, Arcadia Biosciences Inc (RKDA) has total liabilities worth $3.14 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Arcadia Biosciences Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Arcadia Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Arcadia Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Arcadia Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Duta Anggada Realty Tbk
JK:DART
|
Indonesia | Rp4.89 Trillion |
|
Wästbygg Gruppen AB (publ)
ST:WBGR-B
|
Sweden | Skr1.43 Billion |
|
HIKARI TSUSHIN
MU:HIK
|
Germany | €1.26 Trillion |
|
ARHT Media Inc
OTCQB:ARHTF
|
USA | $8.00 Million |
|
AKS Corporation Public Company Limited
BK:AKS
|
Thailand | ฿4.41 Billion |
|
XP Chemistries AB
ST:XPC
|
Sweden | Skr1.09 Million |
|
Nl Development Public Company Limited
BK:NL
|
Thailand | ฿842.38 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Arcadia Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.67 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arcadia Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arcadia Biosciences Inc (2012–2024)
The table below shows the annual total liabilities of Arcadia Biosciences Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $7.29 Million | +4.17% |
| 2023-12-31 | $7.00 Million | -12.72% |
| 2022-12-31 | $8.02 Million | -36.94% |
| 2021-12-31 | $12.72 Million | -32.32% |
| 2020-12-31 | $18.80 Million | -22.48% |
| 2019-12-31 | $24.25 Million | +116.33% |
| 2018-12-31 | $11.21 Million | +30.90% |
| 2017-12-31 | $8.56 Million | -75.09% |
| 2016-12-31 | $34.38 Million | +1.06% |
| 2015-12-31 | $34.02 Million | +27.05% |
| 2014-12-31 | $26.77 Million | -0.24% |
| 2013-12-31 | $26.84 Million | +40.94% |
| 2012-12-31 | $19.04 Million | -- |